Saturday 17 October 2026
Export NRXS’s income statement to Excel — free account
Neuraxis, Inc.
NRXS Healthcare Biotechnology
Neuraxis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 115.7%, EPS grew 13.6% and free cash flow grew 29.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.70
0.04
−0.52%
Follow NRXS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
16.67 | 18.92 | 11.55 | 9.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(86.06) | (65.88) | (21.32) | (21.31) | |
P/B ratio |
13.16 | 14.10 | 12.14 | 13.34 | |
Price to Tangible BV |
13.69 | 14.79 | 13.21 | 15.23 | |
EV/Sales |
15.11 | 17.28 | 10.17 | 7.76 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.29) | (12.21) | (5.64) | (4.17) | |
EV/FCF |
(13.89) | (11.87) | (5.50) | (4.09) | |
Quick Ratio |
2.83 | 2.65 | 1.85 | 1.43 | |
Current Ratio |
3.04 | 2.89 | 2.05 | 1.58 | |
Net Debt/EBITDA |
3.95 | 4.11 | 2.93 | 2.10 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.62 | 0.73 | 0.64 | 0.97 | |
Operating CF/Net income |
0.45 | 0.63 | 1.02 | 0.61 | |
Capex/Depreciation |
(0.38) | 0.00 | (4.39) | 0.00 | |
Interest Coverage |
(107.31) | (66.44) | (60.03) | (35.06) | |
Research and Development Expense of Revenue |
14.22% | 6.19% | 13.40% | 16.13% | |
Selling, General and Administrative Expense of Revenue |
181.81% | 188.48% | 249.35% | 326.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.04 | 0.05 | |
Share Based Compensation of Revenue |
33.17% | 20.49% | 16.24% | 19.82% | |
Graham Net Nets |
0.07 | 0.06 | 0.07 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.67%) | (10.95%) | (20.70%) | (31.82%) | |
Free Cash Flow Yield |
(6.53%) | (7.69%) | (16.02%) | (20.95%) | |
Revenue per Share |
0.16 | 0.15 | 0.11 | 0.08 | |
Operating CF per Share |
(0.08) | (0.11) | (0.21) | (0.14) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.11) | (0.22) | (0.14) | |
Cash per Share |
0.69 | 0.65 | 0.55 | 0.44 | |
Shareholders Equity per Share |
0.56 | 0.53 | 0.37 | 0.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.56 | 0.53 | 0.37 | 0.23 | |
Free Cash Flow |
(1.04) | (1.23) | (2.04) | (1.43) | |
Working Capital |
6.32 | 5.33 | 2.94 | 1.84 | |
Capital Expenditures |
(0.01) | — | (0.11) | 0.00 | |
Net Current Asset Value |
6.15 | 5.14 | 2.73 | 1.50 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.11 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.28 | 0.31 | 0.22 | 0.08 | |
Average Payables |
0.63 | 0.42 | 0.37 | 0.92 | |
Average Inventory |
0.20 | 0.14 | 0.15 | 0.07 | |
Average Assets |
8.54 | 5.89 | 5.58 | 3.46 | |
Average Common Equity |
5.49 | 3.00 | 2.73 | 0.24 |
Columns are period end dates